ArticleAntimicrobial agents and chemotherapy2007
Bis-acridines as lead antiparasitic agents: structure-activity analysis of a discrete compound library in vitro.
Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Synthesis, Stability, and Biological Evaluation of Novel Aminoderivatives Incorporating the Aza-Acridine Scaffold.Molecules (Basel, Switzerland) · 2025Article
- Experiments and Calculation on New N,N-Molecules (Basel, Switzerland) · 2024Article
- Nature-Inspired Gallinamides Are Potent Antischistosomal Agents: Inhibition of the Cathepsin B1 Protease Target and Binding Mode Analysis.ACS infectious diseases · 2024Article
- Identification and characterization of topoisomerase III beta poisons.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Molluscicidal and Larvicidal Potency ofPharmaceutics · 2023Article
- A Machine Learning Strategy for Drug Discovery Identifies Anti-Schistosomal Small Molecules.ACS infectious diseases · 2021Article
- Acridine-Based Antimalarials-From the Very First Synthetic Antimalarial to Recent Developments.Molecules (Basel, Switzerland) · 2021Review
- Article
- Targeted Tumor Therapy with Radiolabeled DNA Intercalator: A Possibility? Preclinical Investigations withBioMed research international · 2020Article
- In vitro activity of salinomycin and monensin derivatives against Trypanosoma brucei.Parasites & vectors · 2016Article
- Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni.PLoS neglected tropical diseases · 2015Article
- Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1.Journal of medicinal chemistry · 2013Article
- Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.Biochemical pharmacology · 2010Article
- Improved tricyclic inhibitors of trypanothione reductase by screening and chemical synthesis.ChemMedChem · 2009Article
- Two approaches to discovering and developing new drugs for Chagas disease.Memorias do Instituto Oswaldo Cruz · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 6 institutions in 4 countries.
Funding
Abstract
Parasitic diseases are of enormous public health significance in developing countries-a situation compounded by the toxicity of and resistance to many current chemotherapeutics. We investigated a focused library of 18 structurally diverse bis-acridine compounds for in vitro bioactivity against seven protozoan and one helminth parasite species and compared the bioactivities and the cytotoxicities of these compounds toward various mammalian cell lines. Structure-activity relationships demonstrated the influence of both the bis-acridine linker structure and the terminal acridine heterocycle on potency and cytotoxicity. The bioactivity of polyamine-linked acridines required a minimum linker length of approximately 10 A. Increasing linker length resulted in bioactivity against most parasites but also cytotoxicity toward mammalian cells. N alkylation, but less so N acylation, of the polyamine linker ameliorated cytotoxicity while retaining bioactivity with 50% effective concentration (EC(50)) values similar to or better than those measured for standard drugs. Substitution of the polyamine for either an alkyl or a polyether linker maintained bioactivity and further alleviated cytotoxicity. Polyamine-linked compounds in which the terminal acridine heterocycle had been replaced with an aza-acridine also maintained acceptable therapeutic indices. The most potent compounds recorded low- to mid-nanomolar EC(50) values against Plasmodium falciparum and Trypanosoma brucei; otherwise, low-micromolar potencies were measured. Importantly, the bioactivity of the library was independent of P. falciparum resistance to chloroquine. Compound bioactivity was a function of neither the potential to bis-intercalate DNA nor the inhibition of trypanothione reductase, an important drug target in trypanosomatid parasites. Our approach illustrates the usefulness of screening focused compound libraries against multiple parasite targets. Some of the bis-acridines identified here may represent useful starting points for further lead optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.